News

08/06/2024

Richmond Times-Dispatch Op-Ed: For-profit middlemen are threatening Virginia’s biotech ecosystem

Virginia patients continue to struggle to balance health care costs with other daily living necessities. As state legislators explore different paths to improve access to care for communities across the commonwealth, commonsense solutions that will effectively lower costs and other barriers that patients face at the pharmacy counter must be at the forefront. To improve

07/25/2024

Growth of Early-Stage Resident Companies Marks the Third Anniversary of Johnson & Johnson Innovation – JLABS @ Washington, DC

Celebration of the three-year anniversary of JLABS @ Washington, DC (JLABS DC), it’s great timing to highlight recent accomplishments and milestones reached by incubating and regional companies. Additionally, JLABS DC is excited to share new access to specialized lab equipment to support more innovators within the region. Since the start of 2024, there has been

07/19/2024

Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide

07/18/2024

Virginia Companies Expand into Global Markets through Commonwealth’s Trade Accelerator Program

Governor Glenn Youngkin  announced that 11 companies across the Commonwealth have graduated from the Virginia Economic Development Partnership’s (VEDP) Virginia Leaders in Export Trade (VALET) program and 14 companies have joined the two-year program. VALET, which now has 402 graduated companies, assists Virginia exporters that have firmly established domestic operations and are committed to international

07/18/2024

Robert Ward appointed as Activation Capital’s interim president and chief executive officer

The Virginia Biotechnology Research Park Authority Board appointed Robert Ward as interim president and chief executive officer of Activation Capital, an innovation ecosystem development organization, effective today. Ward is a senior executive with over 25 years of experience leading organizations, driving strategy and innovation, developing high performing teams and executing complex transactions. Ward has served

07/17/2024

Carilion CEO Nancy Howell Agee to Retire

Nancy Howell Agee, who led Carilion through more than a decade of transformative change, will step down as CEO Sept. 30. Steve Arner, who was promoted to president in May 2023, will succeed Agee and become president and CEO Oct. 1. The leadership transition comes after Agee’s long and distinguished career at Carilion, beginning as

07/15/2024

Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some

07/15/2024

Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that

07/12/2024

Director named for Fralin Biomedical Research Institute at VTC Cancer Research Center

An accomplished biomedical engineer who studies the biophysical setting of brain cancer has been named director of the Fralin Biomedical Research Institute at VTC’s Cancer Research Center in Roanoke, Virginia. Jennifer Munson will organize the institute’s Cancer Research Center in Roanoke, while closely collaborating with its Cancer Research Center in Washington, D.C., said Michael Friedlander, Virginia Tech’s vice

07/11/2024

BrightSpec Adds Commercial Firepower to its Leadership Team and Board of Directors

BrightSpec, the market leader in Molecular Rotational Resonance (MRR) spectroscopy solutions, announced the appointment of two new executives to drive the commercialization of their growing portfolio of precision instruments and analytical tools. BrightSpec develops and commercializes instruments that harness the power of MRR spectroscopy, an innovative approach to rapidly and definitively characterize the unique three-dimensional

07/11/2024

BIO-CAT Announces Safety Study on New Enzyme Addressing High FODMAP Foods

BIO-CAT, an industry-leading enzyme supplier headquartered in Virginia, is excited to announce the publication of a groundbreaking safety clinical trial manuscript featuring its proprietary ingredient, OPTIZIOME® Inulinase  (now marketed as OPTIZIOME® Fructanase), in Gastro Hep Advances. Fructanase, also known as inulinase, was developed to address the unintended consequences of digestive discomfort from certain foods, more

07/09/2024

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Accomplished Financial Executive

ReAlta Life Sciences, Inc., a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases,  announced the appointment of Emma Reeve to its Board of Directors, effective immediately. “We are very pleased to welcome Emma Reeve to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta’s Board

07/09/2024

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Corporation announced that Robert (“Bob”) Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital

07/09/2024

Contraline’s First In-Human Trial Shows Safety with 12-Month Efficacy Signals of the ADAM™ Male Contraceptive Device

Contraline, a clinical-stage biotechnology company, has announced promising initial safety and efficacy results from its First-in-Human clinical trial. The trial, which is evaluating the safety and preliminary efficacy of Contraline’s ADAM™, a non-permanent male contraceptive, has had its first patients demonstrate 12 months of efficacy in the study. ADAM™ is a water-soluble, biocompatible, and non-permanent

07/09/2024

Serpin Pharma and HekaBio Sign Term Sheet for Groundbreaking Neuropathy Treatment

Serpin Pharma, a Virginia-based biopharmaceutical company, and HekaBio, headquartered in Tokyo, Japan, have signed a term sheet to develop and commercialize SP163M, a novel peptide drug for preventing chemotherapy-induced peripheral neuropathy (CIPN). SP163M, a groundbreaking discovery by Serpin Pharma, is set to revolutionize pain management. This novel therapy protects nerves from the damaging effects of

07/08/2024

Chandra Briggman is leaving Richmond’s Activation Capital

Chandra Briggman is exiting her role as president and CEO of Richmond’s Activation Capital. The independent authority of Virginia that promotes research, commercialization and innovation ecosystem development in the Richmond region said Monday that Briggman is leaving “to pursue new opportunities to build innovation ecosystems and drive economic development.” She’s been in the role a

07/08/2024

Roquette and Bonumose Sign a Global Cooperation Agreement Supporting Tagatose Growth

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, and Bonumose, a pioneer in enzymatic solutions for rare monosaccharide production, are pleased to announce the signing of a Cooperation Agreement that aims to advance the development of tagatose, a natural-origin sweetener with clinically proven health benefits. This collaboration combines Roquette’s

06/27/2024

Virginia Catalyst announces Grant Round 16 awarded projects!

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.18 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 16. “Powerful collaborations

06/27/2024

Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Quoin Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on rare and orphan diseases,  announced that it will expand its ongoing Netherton Syndrome clinical studies to include international sites. The first international site will be opened at a research hospital in Saudi Arabia. This hospital is currently treating a number of Netherton patients who

06/17/2024

PAK BioSolutions Raises $12 Million Series A to Expand Continuous Biomanufacturing Product Line

PAK BioSolutions announced that it has raised $12M from Arboretum Ventures, BroadOak Capital Partners, and other investors to expand commercial and product development efforts for its line of automated continuous manufacturing systems for biologics. The PAK Pilot System is capable of processing 50-500L of cell culture per day, addressing a major segment of the biopharmaceutical

06/14/2024

EVMS and ODU join forces to create state’s largest health sciences program

Old Dominion University and Eastern Virginia Medical School are joining forces in an effort to grow local medical talent where there’s a great public need. Together EVMS and ODU are now the Macon and Joan Brock Virginia Health Sciences at ODU. The merger creates the largest health sciences program in the Commonwealth. Come July 1,

06/12/2024

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland. The scope of the agreement encompasses the development of novel topical formulations of Rapamycin (sirolimus) as potential

06/11/2024

KeViRx, Inc. Awarded $1.99 Million

KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury

05/31/2024

Virginia Catalyst Announces Round 17 of Grant Funding

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 16 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The mission of the Catalyst